Form 4: Guided Therapeutics Director Acquires Shares Through Dividend Conversion

Director John E. Imhoff acquired 183,008 shares of Guided Therapeutics Inc. common stock through the conversion of accrued dividends on Series E preferred stock.

Summary

• On August 21, 2024, John E. Imhoff, a director of Guided Therapeutics Inc., acquired 183,008 shares of common stock.
• The acquisition was a result of converting accrued dividends on his Series E preferred stock at a conversion price of $0.1093 per share.
• Following the transaction, Imhoff directly owns 5,409,231 shares of Guided Therapeutics Inc.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders and their holdings in the company.

Stakeholder Impact

• The transaction increases the number of outstanding shares, which could potentially dilute existing shareholders' ownership.

Key Dates

Keywords

Form 4, Beneficial Ownership, Insider Trading, John E. Imhoff, Guided Therapeutics Inc., GTHP, Dividend Conversion, Series E Preferred Stock, Director